BRII-B (02137) released its 2025 interim results, reporting other income of RMB 28.1 million, representing a 60.4% year-on-year decrease. Research and development expenses totaled RMB 117 million, down 7.3% compared to the same period last year. The company recorded a loss of approximately RMB 149 million during the period, declining 47.5% year-on-year. Loss attributable to owners of the company was approximately RMB 148 million, decreasing 47.22% year-on-year.

The announcement indicated that the reduction in R&D expenses reflects standardized pipeline prioritization and organizational streamlining during the reporting period, while maintaining continued investment in core programs. The decreased losses were primarily attributable to a RMB 115.5 million reduction in net other losses mainly related to fair value changes of equity investments, a RMB 33 million decrease in net impairment losses under the expected credit loss model, and reduced operating expenses.

During the first half of 2025, the company achieved a significant milestone with the out-licensing of soralimixin (BRII-693), a novel investigational polymyxin antibiotic for treating severe MDR/XDR gram-negative bacterial infections. In July 2025, the company announced a collaboration with Jiankun Group, granting Jiankun Group the rights to research, develop, and commercialize soralimixin (BRII-693) in Greater China.

This partnership enables the company to continue focusing its internal resources on core HBV programs while advancing the regional development and commercialization of soralimixin (BRII-693). In addition to accelerating access to urgently needed anti-infective treatments in Greater China, clinical data generated by Jiankun Group during development may also support the development of soralimixin (BRII-693) in other regions.